The U.S. cell and gene therapy clinical trials market, valued at USD 5.36 billion in 2024, is projected to grow at a compound annual growth rate (CAGR) of 15.3% from 2025 to 2034, driven by accelerating innovation in personalized medicine and robust federal support for advanced therapeutics. While the United States remains the global epicenter for cell and gene therapy (CGT) research—accounting for over 50% of all active clinical trials globally—regional dynamics in Europe and Asia Pacific are increasingly shaping the competitive landscape. North America’s dominance is underpinned by a dense network of academic research institutions, well-established regulatory pathways through the FDA’s Center for Biologics Evaluation and Research (CBER), and deep venture capital funding. The U.S. also benefits from a mature ecosystem of contract development and manufacturing organizations (CDMOs), enabling rapid translation from bench to bedside. However, geopolitical factors, regulatory divergence, and evolving cross-border supply chains are creating both opportunities and constraints for multinational trial execution.
In Europe, the European Medicines Agency (EMA) has implemented adaptive licensing frameworks and priority medicines (PRIME) designation to accelerate CGT development, mirroring aspects of the FDA’s regenerative medicine advanced therapy (RMAT) pathway. Countries like Germany, the UK, and Belgium are emerging as regional innovation hubs, supported by national funding initiatives such as Germany’s Federal Ministry of Education and Research (BMBF) grants and the UK’s Advanced Therapy Treatment Centres (ATTCs). Despite these advances, fragmented reimbursement policies across EU member states and inconsistent ethical review timelines create operational inefficiencies that hinder large-scale trial harmonization. Moreover, the EU’s Clinical Trials Regulation (CTR), implemented in 2022, aims to streamline approvals but has faced delays in full adoption, affecting cross-border trial coordination and patient recruitment.
Read More @ https://www.polarismarketresearch.com/industry-analysis/us-cell-and-gene-therapy-clinical-trials-market
Asia Pacific is witnessing rapid expansion in CGT clinical activity, particularly in China, Japan, and South Korea, where national policy impact is driving aggressive investment in biotech infrastructure. China’s National Medical Products Administration (NMPA) has expedited review processes for gene-edited therapies, while Japan’s conditional early approval system (SAKIGAKE) has enabled faster market access for regenerative medicines. These regulatory tailwinds, combined with lower trial costs and large patient pools, have attracted U.S.-based sponsors to establish joint ventures and satellite research centers in the region. However, intellectual property concerns, data localization requirements, and export controls on genetically modified materials complicate cross-border supply chains, particularly for autologous therapies requiring patient cell shipment and centralized manufacturing.
Regional manufacturing trends are shifting toward decentralized, regionalized production models to address logistical challenges associated with cold chain logistics and short product shelf lives. The U.S. is pioneering modular, closed-system bioreactor platforms and point-of-care manufacturing technologies to reduce reliance on centralized facilities. In contrast, Europe is investing in cross-border manufacturing networks under the European Health Union initiative, while China is expanding its domestic plasmid DNA and viral vector capacity to reduce dependence on Western suppliers. These developments reflect divergent market penetration strategies: U.S. firms focus on technological leadership and IP control, while Asian counterparts prioritize scale and cost efficiency. As global competition intensifies, the ability to navigate regulatory heterogeneity, secure supply chain resilience, and maintain ethical compliance will determine long-term success in the CGT clinical trials arena.
Competitive Landscape:
- Novartis AG
- Gilead Sciences, Inc.
- Bristol-Myers Squibb Company
- Jazz Pharmaceuticals plc
- Bluebird Bio, Inc.
- CRISPR Therapeutics AG
- Celgene Corporation (a Bristol-Myers Squibb subsidiary)
- Kite Pharma (a Gilead Sciences company)
More Trending Latest Reports By Polaris Market Research:
Allergy Diagnostics and Therapeutics Market
North America Metal Emblem And Logos Market
Asia Pacific Organic Cereals Market